Abstract. Standardized methods for the detection and assessment of circulating tumor DNA (ctDNA) in breast cancer are not sufficient. In the present study, the method and the potential application of ctDNA in the diagnosis of breast cancer were explored. DNA was extracted from the tumor tissues, plasma and peripheral blood cells of 11 patients with early-stage invasive breast cancer. Primers were designed against the exons of phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit α, p53, epidermal growth factor receptor, Akt and phosphatase and tensin homolog. The amplicon-based method for whole-exon sequencing was performed. The associations between the ctDNA mutant frequency with the tumor DNA mutant frequency, and the ctDNA concentration with clinical data were analyzed. A linear association was identified between the concentration of ctDNA and the tumor volume for the 3 patients with basal-like breast cancer, and not in other subtypes. The mutation frequency differed the least between ctDNA and tissue DNA in basal-like breast cancer. ctDNA retained the constituent ratio of gene mutations identified in the corresponding tumor tissue. The ctDNA detection rate depended to a certain extent on the mutation frequency in tumor tissue; for example, a mutant locus with a mutation frequency of >30% in tissues presented a detection rate of >40% in plasma samples, whereas a locus with a mutation frequency of <10% in tissue was associated with a detection rate of ≤1% in the plasma. Therefore, ctDNA may reflect the mutations observed in cancer. Compared with other subtypes, ctDNA may be a more sensitive biomarker for the assessment of mutation and cancer burden in basal-like breast cancer relative to other subtypes.
Introduction
At present, the incidence rate for breast cancer is 1/26 in women aged <65 years in China (1) . This situation highlights the urgent requirement for improvement in prevention and treatment, making it necessary to search for effective strategies for the early diagnosis and monitoring of breast cancer. Circulating tumor (ct)DNA, which carries tumor-specific sequence alterations, is present in the cell-free fraction of blood, representing a variable, although generally small, fraction of the total circulating cell-free (cf)DNA (2, 3) . The detection of ctDNA may provide novel strategies for cancer diagnosis and monitoring. The non-invasive analysis of tumor-derived DNA may serve an important role in the identification and analysis of solid tumors, potentially overcoming the limitations of repeated biopsies (4, 5) . ctDNA exhibits a more significant association with tumor burden than carcinoma antigen 15-3 or circulating tumor cells (6) . It has been demonstrated as a potential tool for monitoring metastatic breast cancer with high sensitivity (6) . ctDNA may also be used to analyze the mechanisms underlying acquired drug resistance to guide the strategy of tumor management (7) . The digital droplet polymerase chain reaction can be applied to monitor ctDNA even in early-stage breast cancer (8) . However, the ctDNA detection rate was low in a previous study, due to the limited number of genes and loci analyzed (9) . A low detection rate may restrict the feasibility of applying ctDNA analysis.
The aim of the present study was to explore the potential application of ctDNA. Amplicon sequencing was performed on DNA extracted from tumor tissues, plasma and peripheral blood cells in a total of 33 samples from 11 patients with invasive breast cancer. The ratio of gene mutation between ctDNA and tumor DNA was analyzed. In addition, its potential role in monitoring the tumor burden in patients with breast cancer was assessed. 
Assessment of basal-like

Materials and methods
Sample collection and processing. A total of 11 patients were selected randomly. These patients were all classified as early-stage tumor node metastasis (TNM) stage I/II (10) . The tumor tissues were collected through surgical resection of breast tumors and the matched blood samples were collected before surgery. All the specimens were stored at Heilongjiang Province Breast Bio-Sample Bank (Harbin, China). Matched DNA from tumor tissues, plasma and peripheral blood cells were extracted. The patients ranged in age from 36-61, with a mean age of 48.8 years. All patients provided signed informed consent. The study was approved by the Ethical Committee of Harbin Medical University (Harbin, China). Blood collected in EDTA tubes was processed within 1 h of sample collection and centrifuged at 4˚C, 820 x g for 10 min to separate the plasma from the peripheral blood cells. The plasma was transferred to microcentrifuge tubes and centrifuged at 4˚C, 20,000 x g for 10 min to remove cell debris. Cell-free DNA was extracted from 2-ml aliquots of cell-free plasma using the QIAamp Ultra Sens Virus kit (Qiagen China Co., Ltd., Shanghai, China) according to the manufacturer's protocol. The cell pellet from the initial centrifugation step was used for the isolation of germline genomic DNA using Pure Link Genomic DNA kits (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Matched tumor DNA was isolated from breast cancer tissues using Pure Link Genomic DNA kits (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Sequencing and data analyses. The 5 most commonly mutated genes in breast cancer were identified in The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/). The primers used in the amplification of these genes are included in Table I Table IV . Linear-regression analysis was used to evaluate the association between ctDNA concentration and tumor volume in basal-like breast cancer. P<0.05 was considered to indicate a statistically significant difference.
Results
Amplicon sequencing. Phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit α, TP53, epidermal growth factor receptor, Akt and phosphatase and tensin homolog were identified as the most commonly mutated in breast cancer, according to TCGA. Primers were designed for these genes and the amplicon-based method for whole-exon sequencing was performed on DNA samples from 11 patients with invasive breast cancer from the Heilongjiang Province Breast Bio-Sample Bank, including from tumor tissues, plasma and peripheral blood cells. Ion torrent sequencing was performed; this achieved 98.95% coverage based on a mean sequencing depth of 4,920 reads/sample. The sequenced DNA fragments were 25.2 kb, and the amplicon length was 125-275 bp (coverage >10, quality >100, strand bias <0.8).
Association between the ctDNA mutation rate and clinical data. Subsequent to excluding single-nucleotide polymorphisms (SNPs) detected in the peripheral blood cells, the mean mutation frequencies of the 5 genes for each patient (tested in plasma and tissues) are listed in Table IV . A total of 3/11 patients exhibited the basal-like subtype. Of the patients with the basal-like subtype, the difference in the mutation frequencies between tumor tissues and plasma samples (tissue-plasma) was the lowest in patients 2 and 6, whereas the mutation frequency in plasma was higher than in the tumor tissue of patient 7. Therefore, it was demonstrated that the amount of DNA released from tumor tissues to circulating blood in the basal-like subtype was generally increased compared with that in other subtypes (P=0.048). We hypothesized that this was caused by the high proliferative activity and elevated level of necrosis and apoptosis associated with the basal-like subtype (11) .
The effect on cell survival and growth of particular mutations lead to an alteration in the mutation compositions between plasma and tumor tissues. To further elucidate this issue, the constituent ratios of gene mutations in plasma and tumor tissues were analyzed (Table III) . However, no significant difference in the constituent ratios of gene mutations were observed between plasma and tumor tissues (P= 0.917, Mann-Whitney test). On account of the similarity in the constituent ratios identified in tumor tissues and plasma in the present study, ctDNA may be useful to track the clonal evolution of tumors.
Comparison of the ctDNA concentration with clinical data.
The concentration of ctDNA was previously demonstrated as a biomarker for the assessment of cancer burden. This was verified in the present study. Multiplying the concentration of cfDNA, as determined by a previously determined method (12) , by the mutation frequency of ctDNA, yielded the concentration of ctDNA. The mean value for the mutation frequencies of the genes was used as the ctDNA mutation frequency. The clinical data and ctDNA concentrations of the 11 patients are summarized in Table V . CCCTGTCATCTTCTGTCCCTT  AMPL7152996965 CCCAATTGCAGGTAAAACAGTCA  AGCACTAAGCGAGGTAAGCAAG  AMPL7152996966 AAGCTATGATGTTCCTTAGATTAGGTGTAT  CCAGACCAGCTTTCAAAAAGAAAATTGTTA  AMPL7152996967 TCATAGGGCACCACCACACTAT  CATGGCCATCTACAAGCAGTCA  AMPL7152996968 CATTCTGGGAGCTTCATCTGGA  CGTTCTGGTAAGGACAAGGGTT  AMPL7152996970 TGTGATGAGAGGTGGATGGGTA  CCTCATCTTGGGCCTGTGTTAT  AMPL7152996971 CAGGAAGTCTGAAAGACAAGAGCA  CCAGGGTTGGAAGTGTCTCATG  AMPL7152996972 ATTGCAAGCAAGGGTTCAAAGAC  GCCTTAGGCCCTTCAAAGCATT  AMPL7153002870 AGTGCTTGTTGCTTGCCAG  GGATGTGGACCAACGTGAGG  AMPL7153002873 CCTTCTTGAGCAGCCCTGAAA  CATGTACGAGATGATGTGCGGT  AMPL7153002898 GCGTACTCCATGACAAAGCAGA  GTATCAGGCGACGTGGTATCAA  AMPL7153004003 CGACCCAGTTACCATAGCAATTTAGT  GAAAACTGTTCCAATACATGGAAGGATG  AMPL7153004013 GATCAAGAAATCGATAGCATTTGCAGTATAG  CTCCTAGAATTAAACACACATCACATACAT  ACA  AMPL7153004026 CACGACGGGAAGACAAGTTCAT  CAAAACACCTGCAGATCTAATAGAAAACAA  AMPL7153004031 GTTAGCTCATTTTTGTTAATGGTGGCTT  CTCACTCTAACAAGCAGATAACTTTCACTT  AMPL7153004036 TTTTTCTTATTCTGAGGTTATCTTTTTACCACA CCTCTTGTGCCTTTAAAAATTTGCC  AMPL7153004059 GCCATTTCCATCCTGCAGAAGA  CCAAACTACGGACATTTTCGCATC  AMPL7153007063 TCTTCTCCGAGTGCAGGTAGT  GTTAGGGCTTCTGAGACTTTCCAG  AMPL7153007092 TCAAATGCACCCGAGAAATAAAAACC  CCGTGCTTTAAGAGGTTGGCTT  AMPL7153007099 CACCAGGAAGCCACTCAGATG  GTGGCTATTGTGAAGGAGGGTT  AMPL7153007111 CGCCCTACATGGAAAACCG  CTCACCCAGTGACAACTCAGG  AMPL7153007146 GGCAGGACTCGGCATCAAG  GAACCTCATGCTGGACAAGGA  AMPL7153007158 CCAGTTTTTATCTCCAGCCTCAGTT  AGTGGACCACTGTCATCGAAC  AMPL7153007172 AAATGAGGACCAGGCCAGTTT  GCTTCTTTGCCGGTATCGTGT  AMPL7153007194 CCACCTCGTCCTGTAAAGCAG  CTGCCCATAGACCATGAACGA  AMPL7153009985 CTGTTAGGATCAGATTATAGTGTTACACCA  TGCCATCATTACTTTGATTACAGGATGAT  AMPL7153010057 GGACTATGTCCGGGAACACAAA  ATGGCAAACTCTTGCTATCCCA  AMPL7153010068 ATGTCAGCCGAGGCAGGGAAT  GGGCAAAGAATAAAAGGAAGAGAAAAT  CAA  AMPL7153010138 CCACGTACCAGATGGATGTGAAC  GACTCTCCAAGATGGGATACTCCA  AMPL7153011255 GCAAAGACCTGAAGGTATTAACATCATT  AGAGCCAAGCATCATTGAGAAAAGATTTA  AMPL7153011364 ATGTTACTTTTAAAATGAAAAACCTTACA  ACAGTCCATTGGCAGTTGAGAATAAA  GGAA  AMPL7153011377 CTTCCAAATCTACAGAGTTCCCTGTT  AGTCCTGTACTTCTGGATCTTTAACCATAT  AMPL7153017580 TGGGATGGTGCTTTGCTGATTA  GTCGAATGTGCTGTTGACACAG  AMPL7153017625 TCGCATCACCAATGCCTTCTTTA  GGCATGTGACAGAACACAGTGA  AMPL7153017648 ATGATTTTTCTTCTCTCCAATGTAGTGGT  GGACCCATTAGAACCAACTCCATAAA  AMPL7153017672 TGCCTGTGGATCCCTAGCTATT  TGATCACCAATCTCTACCAGTTAAAAAGG  AMPL7153017708 ATCGGCCTCTTCATGCGAA  CACATTCAGAGATTCTTTCTGCATCATAAT  AMPL7153017718 ATCCAACATCCAGACACATAGTGATTTT  GAGGACAGTCAGAAATGCAGGAA  AMPL7153017742 ACACCTTCACAATATACCCTCCATGA  CAGGAAGAAAACTCAAGATTATCTGGGTTA  AMPL7153017760 GCAGTTGGGCACTTTTGAAGAT  CCTTTCTCCACTTAGATTTTCTCCAATTTT  AMPL7153017833 GTGTGTCACTCGTAATTAGGTCCA  CGAAAGAAAATACTTGCATGTCAGAGGATA  AMPL7153017844 TCTCTTTAGCAGAACATAAATGCGAAGA  CATAGGAGCTGGAGGCAGAGATA  AMPL7153017850 TTTGAAAGAGAAAAGAAAGAGACATGCATG TCTCTGAATTTGCAAGAGAGGAAATGTT  AMPL7153017856 GGGAAATGATCCTACCCTCACTCT  CCCACAGGAAGTCTTCTGTCCT  AMPL7153017910 CTGGTAACATCCACCCAGATCA  GCTGCCAGACATGAGAAAAGGT  AMPL7153017922 GACTCCGTCCAGTATTGATCGG  ATCTCAAGGAAACAGGAAAGGACG  AMPL7153017944 TATAATACAGAGTCCCTGAGAGTCTAGAGT  TGCCCTATCTTAGCAACTCTCCT  AMPL7153019495 TTCTTTGTAGATATGATGCAGCCATTGA  CTTGTGATCCAAAAAGTGTCCAAAATCTAT  AMPL7153019513 TACTCCTCTTTCAGAATGTTACCTTATGGT TGTTCTAACTCAGAGGAATACACAAACAC AGCATAAAACTAGTTAGTGCAGTAGGTTTT  AMPL7153019565 AGTTTGGGACTTCTTAAGAAGATTCATATGG  TTTATTTATGTGGACTTTCTGAGAGAAAAC  AAT  AMPL7153019574 TCCCTTGAAAAATGAAAGAGAGATGGT  GCAATTACTTGTTCTGGTACACAGTCAT  AMPL7153019590 GCTTTCCTGAAGTTTCTTTTGAAGAGT  GGATAACTTTCAACATACAGGTTGCCTT  AMPL7153019600 TTAGGAATGGATTCCTAAATAAAAATTGAGGT  CAATTCAACCACAGTGGCCTTT  AMPL7153019614 CAGTCTTGCTTCTGTCTCTGAGT  CATGAAATCTGGTCGCCTCATTT  AMPL7153019630 GGGACAACCATACATCTAATTCCTTAAAGT  AAGAAGATTCATCTTGAAGAAGTTGAT  GGA  AMPL7153019653 AATATTATGTCTTAGATTGGTTCTTTCCTGTC  GCTGTTCTTTGTCATTTTCCCTTAATTCAT  AMPL7153019708 GTTTGATTACACAGACACTCTAGTATCTGG  ATAAGAGAGAAGGTTTGACTGCCATAA  AAA  AMPL7153019717 TTTGGTTGATCTTTGTCTTCGTGATTTG  AAAAATTCAATCAGCGGTATAATCAGGAG  AMPL7153019725 TTCAAAAATGAGTGTTTAAATTGTTTAGCAAAG TGCTTCAAATACATCCCACATGCA  AMPL7153019740 GTAGTCTGATGTCTCCATTGTTATTAGTGG  AAGGGTTCTCCTCCATGGTAGAT  AMPL7152996430 ACAACCTCCGTCATGTGCT  CTTTCAACTCTGTCTCCTTCCTCTTC  AMPL7152996432 GCTGCCCTGGTAGGTTTTCTG  CGATATTGAACAATGGTTCACTGAAGAC  AMPL7152996963 GAGAATGGAATCCTATGGCTTTCCA  CCGTCATAAAGTCAAACAATTGTAACTTGA  AMPL7152996964 GGGTTATAGGGAGGTCAAATAAGCA  GGCCTCTGATTCCTCACTGATTG  AMPL7152996969 AAGGTGATAAAAGTGAATCTGAGGCAT  AATGGGACAGGTAGGACCTGAT  AMPL7152996973 GGGACTGTAGATGGGTGAAAAGA  AACTGTGAGTGGATCCATTGGAAG  AMPL7152996974 TCAACTTACGACGAGTTTATCAGGAAG  CTTCTTGACTGTTTTACCTGCAATTGG  AMPL7153002838 TTTTTAGGACAAAATGTTTCACTTTTGGG  TTCCTTGTCATTATCTGCACGCT  AMPL7153002851 ACGAACTGGTGTAATGATATGTGCATATTT  CTCAGATCCAGGAAGAGGAAAGGAAAAA  AMPL7153004023 ATCGTTTTTGACAGTTTGACAGTTAAAGG  CGGCTGAGGGAACTCAAAGTAC  AMPL7153004043 GTGTCACATTATAAAGATTCAGGCAATGTT  ATGTATCTCACTCGATAATCTGGATGACT  AMPL7153004047 TTGATTGCTGCATATTTCAGATATTTCTTTCC  TGGCTTAGAAATCTTTTCTAAATGAAAAC  ACAA  AMPL7153004054 AAGATGAGTCATATTTGTGGGTTTTCATTTTAA TTATTTTCATGGTGTTTTATCCCTCTTGAT  AAA  AMPL7153007059 CAGCCCGAAGTCTGTGATCTTA  TATGGCGCTGAGATTGTGTCAG  AMPL7153007073 CGCCACAGAGAAGTTGTTGAG  GGGTCTGACGGGTAGAGTGT  AMPL7153007080 CTTCTCATGGTCCTGGTTGTAGAAG  GTCCTGAGCACACGCAATG  AMPL7153007104 GGGTACTAACCTCGTTTGTGCA  CACATTCAGCTTCCTTTGCTTCTC  AMPL7153007116 AGGGACACCTCCATCTCTTCAG  TGGAGCTCCTGATCTGGTACAG  AMPL7153007123 GCCTCTCTGAGTGTGGAGAGAA  TGAAGGTCTTGAGCACACTTGAG  AMPL7153007132 CCTGGAAAGTCTCAGAAGCCCTA  GCCCTGAAGTACTCTTTCCAGA  AMPL7153007163 CTCAGGAGTCTCCACATGGAAG  CTCTGTGAGGCGAGAAACTGAG  AMPL7153007177 GCACCTTCTTCTCGTACACGT  GGCCCTACATCACAGGAGGAA  AMPL7153007184 CTCACGTGCCCAAGAAGACAGGA  CATGAAGATCCTCAAGAAGGAAGTCA  AMPL7153007197 CAGCAGCTTCAGGTACTCAAAC  CAGCCATGTGTTCCCTGTAAG  AMPL7153011276 TCAGAAGTTAAGGCAGTGTTTTAGATGG  GTCCAGAAGTTCCATAGCCTGTTC  AMPL7153011349 ATTTTACAGAGTAACAGACTAGCTAGAGACA  GAAAAAGAAACAGAGAATCTCCATTTTA  GCA  AMPL7153017587 CCGAGTATCTCAACACTGTCCA  CTGGATTTTTAGGGCTCATACTATCCTC  AMPL7153017599 AGTCACAGGTTCAGTTGCTTGT  CAGAAGAAATGTTTTTATTCCAAGGGA  ACA  AMPL7153017611 CCCAACTCCTTGACCATTACCTC  CCATCATCACTGTTCGGCTTCT  AMPL7153017641 ACCTACCATCATTGGAAAGCAGT  CTGACGACTGCAAGAGAAAACTG  AMPL7153017661 GCATGAACATGACCCTGAATTCG  CAGGAAAATGCTGGCTGACCTA  AMPL7153017684 TGTGATTGTTCATTCATGATCCCACT  GCCTCAGCTGTTTGGCTAAGAG  AMPL7153017693 GCCAAGAAGTGGAATAGCATCTCT GAGTAGACACAGCTTGAGAGAGAGA
The scatter plot comparing the ctDNA concentration with tumor volume demonstrated a non-linear association for the majority of the patients (Fig. 1) . However, the ctDNA concentration vs. tumor volume demonstrated a highly linear association in the 3 patients with basal-like breast cancer (R 2 = 0.999, P= 0.018). Therefore, ctDNA may provide an effective assessment regarding tumor burden in patients with basal-like breast cancer.
Function of circulating blood cell samples and tumor tissue samples in ctDNA detection. SNPs in the cfDNA were excluded by collectively examining the mutations identified in the blood cell samples. Tumor tissues were used to verify the reliability of ctDNA and exclude the possibility of an unknown source of cfDNA contributing sequence variants that are not SNPs and that do not exist in tumor tissue. SNPs constituted 68% (173/253) of all the single nucleotide variants (SNVs) in cfDNA. Somatic mutations derived from tumor tissues accounted for 26% (65/253). The remaining variants were SNVs of unknown source (15/253, 6%; Table II ). As SNPs accounted for most of the SNVs in cfDNA, the detection of germline SNPs should be coupled with ctDNA detection to exclude SNPs from the assessment of cancer burden or prediction of drug sensitivity. There were a limited number of unknown source SNVs, which may have affected the result, even though the number was limited. Therefore, the simultaneous detection of variation between tumor tissue samples and plasma samples was determined to be necessary for accurate data analysis.
Effect of the mutation frequency in tumor tissue on the ctDNA detection rate. The present study identified a similarity in the mutation frequency between tumor tissues and ctDNA in basal-like breast cancer. To determine whether a higher mutation detection rate in ctDNA was observed in patients with basal-like breast cancer, the detection rates across molecular subtypes were compared (Table II) . It was demonstrated that basal-like and Her2-positive breast cancer exhibited a markedly increased mutation detection rate compared with the luminal subtype (P= 0.033). It was hypothesized that the cause may be the increased frequency of mutations in the two TTTTTCTCCTTTTAGAAGCTACATAGTGTC TGCGCTTCCGAACGATGT  AMPL7153017730 CCTCAAAAGAGAAATCACGCATTTATGT  CTGCTGTCTGCATTTATGAACCC  AMPL7153017753 GAGTCTCTGTGTGGAGAGAGTGA  ATCCTCTGGAGGCTGAGAAAATG  AMPL7153017791 AAAGCCATGTTATTCTGCCTTTTTAAACT  GAACAGACACGTGAAGGCATG  AMPL7153017821 GCCTGCCCAACCTACTAATCAG  GGTTGAGGAGCAGGACTGTTTC  AMPL7153017863 GTACGTATTTTGAAACTCAAGATCGCAT  CAGGTACTGGGAGCCAATATTGTC  AMPL7153017872 GTAGCCAGCATGTCTGTGTCA  CCAGAAGGTTGCACTTGTCCA  AMPL7153017881 GGGAGGTCCAGAAAGTGATTGG  CCATATGTCAAATGAATAGTGTCAGGACT  AMPL7153017889 GGTGACCCTTGTCTCTGTGTTC  GGAAATATACAGCTTGCAAGGACTCT  AMPL7153017902 CCACCGTCATCACCTTCCTTTC  GAAGAGGAAGATGTGTTCCTTTGGA  AMPL7153017917 GCCAGCCAAACAATCAGAGAATAAG  CCAATCACCTAAGCAAGTGAAGGA  AMPL7153017929 GCTGGGTTTTCCCACACTAGTG  GGTGGCACCAAAGCTGTATTTG  AMPL7153019490 CTTTGGTCAGGGAACATCTGGA  CAGCACATGAACGTGTAAACAGG  AMPL7153019505 GGAAAGGCAGTAAAGGTCATGCA  CACAGTCACCGATTGACAGACA  AMPL7153019527 CGACAGCATGCCAATCTCTTCA  CCAGAGTGAGCTTTCATTTTCTCAGTTA  AMPL7153019540 TTTCTTTAGATCGGCCATGCAGAA  ACTCTTCCAGCCAAACATAAACAAAAGTATATA  AMPL7153019581 ACAAGCAGAAGTATACTCTGAAAATCA  ACAGATACTCATCCTCAATGTGATTACTTT  ACC  AMPL7153019606 GAGTGTCGAATTATGTCCTCTGCAA  AAATGGCTTTCAGTAGTTTTCATGGTTC  AMPL7153019620 TCAGGTACAGATGAAGTTTTTAGTTGAGC GTAGGAGAATGAGAGAGAGAAGCATAAATT  AMPL7153019634 GCATGAACTATTTAAAGAAGCAAGA  GAATAGGATATTGTATCATACCAATTTCT  AAATACCC  CGA  AMPL7153019643 TTATGGCAGTCAAACCTTCTCTCTTATG  GGATCCTTTTCCATAGAGAAAGTATCTACC  AMPL7153019670 TGGACACTTTTTGGATCACAAGAAGA  GATTGTTTCTAATAGAGCAGCCAGAACT  AMPL7153019681 ATTTGATGTTGATGGCTAAAGAAAGCC  AAATAATAAGCATCAGCATTTGACTTTACC  AMPL7153019694 GGCATGCCAGTGTGTGAATTTG  ACAGGTAGAAGACTGCACTATAGTAATGAT  AMPL7153019702 GGGAAAAAGGAAAGAATGGGCTT  TGGCCAAAGATTCAAAGCCATTTTT  AMPL7153019732 CCTGCTTTTGGAGTCCTATTGTCG  AAAAGAGTCTCAAACACAAACTAGAGTCA  AMPL7153019748 TTTTTCTTTTAGATCTATGTTCGAACAGGT CTGGCCAGTGCCTAGCTAATTT The primers were manufactured specifically for use with the Ion AmpliSeq Kits and contain proprietary modifications. molecular subtypes. To further examine this hypothesis, the distribution of mutations derived from tumor tissue in circulating DNA was analyzed (Fig. 2) .
A mutant locus with a mutation frequency of >30% in tissues presented a detection rate of >40% in plasma. An additional locus with a <10% mutation frequency in tissue samples exhibited a detection rate of ≤1% in the plasma. A low positive detection rate may be limited by the sensitivity of the detection methods and the number of detected loci. Therefore, the detection rate may be increased by improving the detection sensitivity or increasing the number of detected genes.
Discussion
To the best of our knowledge, the present study is the first to identify a distinction between ctDNA across molecular subtypes. The mutation frequency differed the least between ctDNA and tissue DNA in basal-like breast cancer. Additionally, the association between ctDNA concentration and tumor volume was linear in basal-like breast cancer. Based on these results, ctDNA detection appears to be a Table II . SNV component of cfDNA. Table III . Constituent ratio of gene mutation in plasma and tumor tissue.
Mutation rate, % Constituent ratio Average mutation rate, promising technique for the assessment of cancer burden in basal-like breast cancer. It has been suggested that ctDNA is a highly sensitive biomarker of metastatic breast cancer (6) . However, there is little evidence concerning the significance of tumor burden assessment in primary breast cancer, particularly early-stage breast cancer; the present study demonstrated that ctDNA may allow the assessment of tumor burden in the basal-like subtype of early-stage breast cancer, not in other subtypes.
Understanding the factors that influence the ctDNA detection rate is beneficial to ensure the accuracy of the results. The present study demonstrated that the ctDNA detection rate depended on the mutation frequency in the corresponding tumor tissues. In a previous study, ctDNA was detectable in 50% of samples from patients with localized breast cancer, as assessed by digital PCR of a relatively small number of loci (13) . ctDNA was detected in all patients in the present study, due to the greater number of detected loci vs. the previous study. However, the concentration of circulating DNA varied among patients. Therefore, an increased number of mutant loci are required to accurately assess the concentration of ctDNA and improve the reliability of ctDNA measurement in future studies.
In the present study, the mutations identified in tumor tissues exhibited a similar constituent ratio to the mutations identified in plasma. ctDNA may theoretically be used to track tumor subclonal evolution in order to correctly reflect tumor progression. Therefore, liquid biopsy analysis of clonal evolution may be applicable to analyze the origin of cancer. However, SNPs may seriously affect the mutation frequency and concentration of ctDNA as they accounted for almost 70% of all the SNVs in cfDNA in the present study. Therefore, tumor burden assessment required the detection and exclusion of SNPs. In predictions of sensitivity, tissue samples and SNPs should be detected concurrently to accurately identify mutant loci. In conclusion, the present study indicated that ctDNA may reflect the mutations observed in breast cancer. In basal-like breast cancer, ctDNA may be a particularly sensitive biomarker for the assessment of mutation frequency and cancer burden. Although the detection of circulating DNA was previously reported as a promising method, there are a number of unsolved problems concerning the detection methods, analysis approach and application fields. Previously published ctDNA detection methods employing Tam-Seq (14) or CAPP-Seq (15) may be highly sensitive for the detection and monitoring of ctDNA. However, to further expand the potential clinical applications of ctDNA, additional investigation into the association of mutations with the physical characteristics of each type of cancer is required. The present study suggests that the analysis of ctDNA could be applied clinically to detect and monitor diverse types of malignancy.
